微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 90.01% | -1.94% | 0.23% | 7/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 89.8% | -3.22% | -1.72% | 4/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 91.37% | -0.36% | -0.46% | 8/159 | 51.78% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 91.79% | -0.48% | -1.08% | 7/159 | 22.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 92.8% | 0.81% | 1.2% | 6/159 | 33.25% | 迪哲医药 | 97.73% | 行业排名> |
| 2023-12-31 | 91.7% | -0.16% | -0.58% | 7/159 | 51.39% | 百利天恒 | 97.99% | 行业排名> |
| 2023-09-30 | 92.24% | -0.08% | 0.2% | 6/159 | 32.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-06-30 | 92.05% | 2.7% | 1.34% | 6/159 | 38.45% | 迈威生物 | 98.93% | 行业排名> |
| 2023-03-31 | 90.83% | 4.7% | -1.11% | 7/159 | 52.78% | 迈威生物 | 99.59% | 行业排名> |
| 2022-12-31 | 91.85% | -1.13% | -0.5% | 6/159 | 53.66% | 迈威生物 | 99.8% | 行业排名> |
| 2022-09-30 | 92.31% | -0.71% | 3% | 5/159 | 6.2% | 迈威生物 | 99.46% | 行业排名> |
| 2022-06-30 | 89.62% | -4.3% | -3.53% | 6/159 | 21.37% | 迈威生物 | 99.75% | 行业排名> |
| 2021-12-31 | 92.9% | 0.73% | -0.08% | 6/159 | 55.1% | 迈威生物 | 99.67% | 行业排名> |
| 2021-09-30 | 92.97% | 0.67% | -0.72% | 4/159 | 46.78% | 迈威生物 | 99.44% | 行业排名> |
| 2021-06-30 | 93.65% | 1.38% | 1.54% | 4/159 | 47.23% | 迈威生物 | 98.57% | 行业排名> |
| 2020-12-31 | 92.23% | -0.7% | -0.14% | 5/159 | -145.9% | 首药控股 | 99.93% | 行业排名> |
| 2020-09-30 | 92.36% | 2% | -0.01% | 5/159 | 56.36% | 艾力斯 | 99.41% | 行业排名> |
| 2020-06-30 | 92.37% | 2.06% | 6.48% | 3/159 | 54.11% | 艾力斯 | 98.7% | 行业排名> |
| 2020-03-31 | 86.75% | 2% | -6.6% | 8/159 | 55.23% | 艾力斯 | 99.4% | 行业排名> |
| 2019-12-31 | 92.87% | 2.67% | 2.61% | 3/159 | -1222.98% | 首药控股 | 99.94% | 行业排名> |
| 2019-06-30 | 90.51% | 2% | 0.06% | 4/159 | 55.21% | 泽璟制药 | 99.96% | 行业排名> |
| 2018-12-31 | 90.46% | 0.02% | 0.02% | 6/159 | -208.09% | 微芯生物 | 95.14% | 行业排名> |
| 2017-12-31 | 90.44% | -3.48% | -3.48% | 5/159 | 52.32% | 多瑞医药 | 95.59% | 行业排名> |
| 2016-12-31 | 93.7% | 2% | 2% | 4/159 | 48.19% | 微芯生物 | 95.81% | 行业排名> |